Skip to main content
Presentation
609 Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017
American College of Rheumatology (ACR) Annual Meeting (2017)
  • Iain McInnes, University of Glasgow
  • Gianfranco Ferraccioli, Catholic University of the Sacred Heart
  • MA D'Agostino
  • M Le Bars
  • S. Banerjee
  • H Ahmad
  • Yedid Elbez
  • J Ye
  • Philip Mease, Providence St. Joseph Health
Abstract
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to achieve sustained minimal disease activity (MDA) vs those with normal BMI, independent of biologic and non-biologic DMARD use.3 Moreover, obese pts with PsA respond less favourably to TNFα inhibitors vs normal BMI pts.4,5 In the Phase III ASTRAEA study (NCT01860976),6 abatacept (ABA) significantly improved disease activity and was well tolerated; the primary endpoint of ACR20 at 24 weeks (W) was met.6 We evaluated the relationship beween BMI and ABA response in a post hoc analysis of ASTRAEA.Methods: 
Results: Overall, 212 ABA- and 210 PBO-treated pts had available baseline BMI status. For ABA vs PBO, respectively, 31 (14.6%) vs 39 (18.6%) were underweight/normal, 77 (36.3%) vs 57 (27.1%) were overweight and 104 (49.1%) vs 114 (54.3%) were obese. In the ABA and PBO groups, neither overweight nor obese pts had a significantly lower ACR20 response vs underweight/normal pts in the univariate model. This was confirmed in the multivariate models in overweight and obese pts, respectively, vs underweight/normal pts: ABA: OR (95% CI) 1.215 (0.437, 3.378), p=0.7087 and 0.446 (0.162, 1.228), p=0.1181; PBO: OR (95% CI) 0.554 (0.189, 1.621), p=0.2811 and 0.460 (0.166, 1.271), p=0.1343. Similar results were observed for all other outcomes tested (Figure). Conclusion: 
1. Kumar S, et al. J Eur Acad Dermatol Venereol 2013;27:1293–8.
2. Armstrong AW, et al. Nutr Diabetes 2012;2:e54.
3. Eder L, et al. Ann Rheum Dis 2015;74:813–7.
4. di Minno MN, et al. Arthritis Care Res (Hoboken) 2013;65:141–7.
5. Gremese E, et al. Front Immunol 2014;5:576.
Disciplines
Publication Date
November, 2017
Citation Information
Iain McInnes, Gianfranco Ferraccioli, MA D'Agostino, M Le Bars, et al.. "609 Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017" American College of Rheumatology (ACR) Annual Meeting (2017)
Available at: http://works.bepress.com/philip-mease/162/